Page last updated: 2024-10-15

noc-5

Description

1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene: a nitric oxide donor compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

NOC-5 : A nitroso compound that is triazane in which the nitrogen at position 1 is substituted by an isopropyl group and a 3-aminopropyl group, that at position 2 is substituted by a hydroxy group, and that at position 3 is substituted by an oxo group. It is a nitric oxide donor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135402057
CHEBI ID149521
SCHEMBL ID447433
SCHEMBL ID12143442
MeSH IDM0295344

Synonyms (22)

Synonym
noc-5
noc 5
1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene
n-[3-aminopropyl(propan-2-yl)amino]-n-hydroxynitrous amide
3-(aminopropyl)-1-hydroxy-3-isopropyl-2-oxo-1-triazene
146724-82-5
3-[2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazinyl]-1-propanamine
3-(2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazino)-1-propanamine
n-(3-aminopropyl)-n-hydroxy-n-propan-2-ylnitrous hydrazide
3-(2-hydroxy-1-isopropyl-2-nitrosohydrazino)propane-1-amine
noc5
CHEBI:149521
SCHEMBL447433
SCHEMBL12143442
DTXSID40163461
(z)-[3-aminopropyl(propan-2-yl)amino]-hydroxyimino-oxidoazanium
J-008249
1-propanamine, 3-[2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazinyl]-
cid 1625
CS-0092466
HY-126166
AKOS040754961
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (14.29)18.2507
2000's15 (71.43)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]